Skip Navigation

Cardiovascular Research 1996 31(1):82-92; doi:10.1016/S0008-6363(95)00162-X
© 1996 by European Society of Cardiology
This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Uriuda, Y.
Right arrow Articles by Rydén, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Uriuda, Y.
Right arrow Articles by Rydén, L.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Copyright © 1996, European Society of Cardiology

Coronary venous drug infusion in the ischaemic-reperfused isolated rat heart

Yozo Uriuda1, Qing-Dong Wang, Xing-San Li, Per-Ove Sjöquist, Rolf Nordlander and Lars Rydén*

Department of Cardiology, Karolinska Hospital, Box 110, S-171 76 Stockholm, Sweden

* Corresponding author. Tel. (+ 46-8) 7292171; Fax (+ 46-8) 311044.

Objectives: Coronary venous retroinfusion (CVR) has been used experimentally in large animals for selective drug delivery into ischaemic myocardium. It would be an advantage if CVR could also be used in isolated perfused rat heart models. The aim of the present paper is to develop a regional ischaemic model in the isolated perfused rat heart combined with CVR. Method: Pharmacokinetic study: The spatial distribution of retrogradely infused felodipine (used as a tracer) during regional myocardial ischaemia was investigated. Following occlusion of the left coronary artery, felodipine was administered over a period of 5 min by CVR. Ischaemia-reperfusion study: Following 30 min of stabilisation, 14 rat hearts were subjected to 60 min of regional ischaemia followed by 60 min of reperfusion. Felodipine (0.7 nmol/kg, n = 7) or vehicle (n = 7) was administered by means of CVR. The infusion was given during the last 5 min of ischaemia at a rate of 0.6 ml/min. Results: Pharmacokinetic study: By means of CVR, the compound was distributed specifically into the ischaemic myocardium. The highest tissue concentration was obtained when the coronary vein was occluded during CVR. The maximal concentration in the ischaemic myocardium was 20–70 times that in the non-ischaemic areas. A transmyocardial gradient was noted with higher drug concentration in the subepicardial zone. Ischaemia-reperfusion study: At the end of reperfusion, the recovery of coronary flow, left ventricular developed pressure and double product (DP; LVDP x HR) was 101 ± 7% (mean ± s.e.m.), 99 ± 8% and 98 ± 4% of the pre-ischaemic values, respectively. This was significantly different from the vehicle group (78 ± 5, P < 0.05, 74 ± 6, P < 0.01 and 78 ± 3, P < 0.05). Conclusion: CVR could easily be accomplished in the isolated perfused rat heart. The drug was specifically delivered into the ischaemic myocardium. Felodipine exerted a myocardioprotective effect in isolated rat hearts subjected to 60 min of regional ischaemia followed by 60 min of reperfusion.

KEYWORDS Myocardial ischemia; Reperfusion; Rat, heart; Calcium antagonists; Coronary vein

1 Present address: Department of Surgery II, National Defense, Medical College, 3-2 Namiki, Tokorozawa, Saitama 350, Japan.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.